Erste Asset Management GmbH Increases Stock Holdings in Stryker Corporation $SYK

Key Points

• Erste Asset Management GmbH raised its stake in Stryker Corporation by 20.3% in Q1, acquiring an additional 20,736 shares, bringing its total holdings to 123,026 shares valued at approximately $45.26 million.
• Insider Ronda E. Stryker sold 200,000 shares of the company at an average price of $376.45, decreasing her position by 5.84% and currently owning shares worth about $1.21 billion.
• Stryker's recent earnings report showed an EPS of $3.13, exceeding forecasts, with a revenue increase of 11.1% compared to the prior year, positioning it strongly in the market.

Erste Asset Management GmbH lifted its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 20.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 123,026 shares of the medical technology company's stock after acquiring an additional 20,736 shares during the period. Erste Asset Management GmbH's holdings in Stryker were worth $45,260,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Stryker by 1.1% during the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company's stock valued at $12,306,572,000 after acquiring an additional 361,136 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Stryker by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock valued at $4,000,056,000 after buying an additional 54,693 shares during the period. Northern Trust Corp lifted its position in Stryker by 13.2% during the 4th quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock worth $1,298,426,000 after acquiring an additional 420,153 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Stryker by 13.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company's stock worth $838,640,000 after acquiring an additional 261,058 shares during the period. Finally, GAMMA Investing LLC grew its holdings in Stryker by 43,226.8% during the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock valued at $772,390,000 after purchasing an additional 2,070,133 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.20% of the company's stock.

Stryker Price Performance

SYK opened at $389.9640 on Wednesday. The stock has a fifty day moving average price of $386.87 and a 200 day moving average price of $379.45. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The stock has a market cap of $149.09 billion, a price-to-earnings ratio of 51.65, a PEG ratio of 2.77 and a beta of 0.91. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. During the same period in the previous year, the company earned $2.81 earnings per share. The company's revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's payout ratio is currently 44.50%.

Analysts Set New Price Targets

SYK has been the topic of several recent analyst reports. Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a report on Monday, May 5th. Wells Fargo & Company boosted their price objective on Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a report on Friday, August 1st. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a report on Monday, July 14th. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Fifteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.